Effect of hydrogen inhalation on cardiovascular and interstitial components of pulmonary hypertension in rats
Kuropatkina TA, Gufranov K, Sychev FY, et al. · Pulmonologiya. 2024;34(1):19–30.
Study at a glance
Preclinical
Male Wistar rats with monocrotaline-induced pulmonary hypertension.
Continuous exposure to nominal 4% H₂ in air for 21 days after monocrotaline administration. · Outlet concentration was 4.1±0.3% H₂. The methods list 150 mL/min H₂ and 4 mL/min air; those printed flows cannot mathematically produce 4% H₂, so Hydrogenology does not reconcile them.
Continuous exposure for 21 days.
Hydrogen did not change the principal pulmonary-hypertension cardiovascular measures: right-ventricular systolic pressure was 57±9 versus 58±7 mmHg. Mast-cell counts and several inflammatory/fibrotic lung findings were lower with hydrogen.
Preclinical model. No benefit was found for the principal cardiovascular manifestations of pulmonary hypertension. The article contains an unresolved flow inconsistency: 150 mL/min H₂ plus 4 mL/min air cannot yield the stated 4.1% H₂.
What kind of evidence is this?
Preclinical
Controlled monocrotaline pulmonary-hypertension rat study
Respiratory health
Inhaled H₂
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Male Wistar rats with monocrotaline-induced pulmonary hypertension.
Outcome table reports control n=7, monocrotaline control n=6 and monocrotaline plus H₂ n=6.
Continuous exposure for 21 days.
Continuous exposure to nominal 4% H₂ in air for 21 days after monocrotaline administration.
H₂ mixed with room air — H₂ alone from the generator, not Brown's gas.
Outlet concentration was 4.1±0.3% H₂. The methods list 150 mL/min H₂ and 4 mL/min air; those printed flows cannot mathematically produce 4% H₂, so Hydrogenology does not reconcile them.
150 mL/min H₂ is printed in the methods, but it is internally inconsistent with the printed air flow and measured 4.1% concentration.
No supplemental O₂ was co-delivered; room air was the diluent. The full article does not report an absolute O₂ flow.
Monocrotaline plus room air and solvent-only control groups.
Outcomes and reported result
Right-ventricular pressure and hypertrophy, lung histology, mast cells, fibrosis and TGF-β immunostaining.
Hydrogen did not change the principal pulmonary-hypertension cardiovascular measures: right-ventricular systolic pressure was 57±9 versus 58±7 mmHg. Mast-cell counts and several inflammatory/fibrotic lung findings were lower with hydrogen.
The complete free publisher full article, methods, tables, positive and null results were checked.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Preclinical model. No benefit was found for the principal cardiovascular manifestations of pulmonary hypertension. The article contains an unresolved flow inconsistency: 150 mL/min H₂ plus 4 mL/min air cannot yield the stated 4.1% H₂.
Monocrotaline pulmonary-hypertension model in rats only.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
OpenAlex ID: W4392132150 · DOI: 10.18093/0869-0189-2024-34-1-19-30
Open-access publisher article under CC BY-NC 4.0.
Pulmonologiya full article; full-text extraction checked 8 August 2026.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.